Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Chunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 128

Showing 1-25 of 128 citing articles:

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 144
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 126
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance
Xu Guo, Congying Gao, Dong‐Hua Yang, et al.
Drug Resistance Updates (2023) Vol. 67, pp. 100937-100937
Closed Access | Times Cited: 99
Dynamic regulation of RAS and RAS signaling
Walter Kölch, Dénes Berta, Edina Rosta
Biochemical Journal (2023) Vol. 480, Iss. 1, pp. 1-23
Open Access | Times Cited: 53
Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 24
Targeting KRAS in pancreatic cancer
Sandra Stickler, Barbara H. Rath, Gerhard Hamilton
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 799-805
Open Access | Times Cited: 18
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors
Dan Lu, Yuan Chen, Min Jiang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 32
Protein degradation: expanding the toolbox to restrain cancer drug resistance
Hui Ming, Bowen Li, Jingwen Jiang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 30
Circular RNAs in the KRAS pathway: Emerging players in cancer progression
Md Sadique Hussain, Ehssan Moglad, Muhammad Afzal, et al.
Pathology - Research and Practice (2024) Vol. 256, pp. 155259-155259
Closed Access | Times Cited: 12
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
Caicun Zhou, Chongyang Li, Libo Luo, et al.
Cancer Cell (2024) Vol. 42, Iss. 7, pp. 1286-1300.e8
Closed Access | Times Cited: 11
Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer
Yu Zhang, Liang Liu, Jinpeng Pei, et al.
Oncogene (2024) Vol. 43, Iss. 9, pp. 668-681
Open Access | Times Cited: 8
SPIONs: Superparamagnetic iron oxide-based nanoparticles for the delivery of microRNAi-therapeutics in cancer
Göknur Kara, Bülent Özpolat
Biomedical Microdevices (2024) Vol. 26, Iss. 1
Closed Access | Times Cited: 8
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
Muhammad Tufail, Wendong Wan, Canhua Jiang, et al.
Chemico-Biological Interactions (2024) Vol. 396, pp. 111055-111055
Closed Access | Times Cited: 8
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
The potential of mRNA vaccines in cancer nanomedicine and immunotherapy
Shulin Pan, Rangrang Fan, Bo Han, et al.
Trends in Immunology (2023) Vol. 45, Iss. 1, pp. 20-31
Closed Access | Times Cited: 18
KRAS Hijacks the miRNA Regulatory Pathway in Cancer
Angelina S. Bortoletto, Ronald J. Parchem
Cancer Research (2023) Vol. 83, Iss. 10, pp. 1563-1572
Open Access | Times Cited: 17
Harnessing Ferroptosis to Overcome Drug Resistance in Colorectal Cancer: Promising Therapeutic Approaches
Xiaofei Cheng, Feng Zhao, Bingxin Ke, et al.
Cancers (2023) Vol. 15, Iss. 21, pp. 5209-5209
Open Access | Times Cited: 16
Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
Rafaela Nasser Veiga, Alexandre Luiz Korte de Azevedo, Jaqueline Carvalho de Oliveira, et al.
Journal of Molecular Medicine (2024) Vol. 102, Iss. 4, pp. 479-493
Closed Access | Times Cited: 7
Morindone as a potential therapeutic compound targeting TP53 and KRAS mutations in colorectal cancer cells
Cheok Wui Chee, Najihah Mohd Hashim, Nurshamimi Nor Rashid
Chemico-Biological Interactions (2024) Vol. 392, pp. 110928-110928
Closed Access | Times Cited: 6
Metabolic Response to Small Molecule Therapy in Colorectal Cancer Tracked with Raman Spectroscopy and Metabolomics
Gabriel Cutshaw, Neeraj Joshi, Xiaona Wen, et al.
Angewandte Chemie International Edition (2024)
Closed Access | Times Cited: 6
Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges
Philemon Ubanako, Sheefa Mirza, Paul Ruff, et al.
Frontiers in Molecular Biosciences (2024) Vol. 11
Open Access | Times Cited: 6
Targeting KRASG12C in colorectal cancer: the beginning of a new era
Davide Ciardiello, Brigida Anna Maiorano, Erika Martinelli
ESMO Open (2022) Vol. 8, Iss. 1, pp. 100745-100745
Open Access | Times Cited: 24
Genetic differences between smokers and never-smokers with lung cancer
Piotr Kuśnierczyk
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis
Yunyi Bian, Guangyao Shan, Guoshu Bi, et al.
Redox Biology (2024) Vol. 77, pp. 103361-103361
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top